Exelixis Inc

NASDAQ:EXEL  
25.58
+0.12 (+0.49%)
Products, Regulatory

Exelixis In-Licenses Aurigene's Novel CDK7 Inhibitor, Files IND Application For Phase 1 Clinical Trial In Advanced Solid Tumors

Published: 12/07/2020 13:19 GMT
Exelixis Inc (EXEL) - Exelixis In-licenses Aurigene’s Novel Cdk7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors.
Exelixis Inc - Phase 1 Clinical Trial Expected to Begin in Q1 2021.
Exelixis Inc - Under Terms of Companies' Agreement, Exelixis Will Make an Option Exercise Payment of $12 Million to Aurigene.
Exelixis Inc - Under Terms of Agreement, Aurigene Retains Limited Development and Commercial Rights for India and Russia.
Exelixis-once Co In-licenses Program, Aurigene Will Be Eligible for Clinical Development, Regulatory, Sales Milestones, As Well As Royalties on Sales.